Facebook
Twitter
Telegram
Report an ErrorMirati Therapeutics Balance Sheet 2011-2024 | MRTX
Annual Balance Sheet Mirati Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-184 M | - | - | -46.5 M | -32.7 M | -108 M | -22.4 M | -49.5 M | -6.59 M | -14.2 M | -18.4 M | -9.84 M |
Long Term Debt |
43.7 M | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
7.84 M | 1.34 M | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 999 K | 732 K | 314 K | 133 K | 43 K | 21 K | 33.4 M | 45.2 K | 27.4 K |
Total Current Liabilities |
159 M | 144 M | 71.5 M | 48.9 M | 26.1 M | 13.6 M | 15 M | 9.8 M | 5.4 M | 38.7 M | - | - |
Total Liabilities |
206 M | 192 M | 115 M | 49.9 M | 26.9 M | 14 M | 15.1 M | 9.84 M | 5.42 M | 38.7 M | 5.38 M | 3.76 M |
Deferred Revenue |
- | - | - | 824 K | 371 K | - | - | - | - | - | - | - |
Retained Earnings |
-2.45 B | -1.71 B | -1.13 B | -772 M | -559 M | -461 M | -390 M | -307 M | -242 M | -198 M | -161 M | -137 M |
Total Assets |
1.2 B | 1.59 B | 1.48 B | 432 M | 228 M | 157 M | 63.4 M | 128 M | 33.5 M | 64.5 M | 39.8 M | 31 M |
Cash and Cash Equivalents |
235 M | 413 M | 886 M | 46.5 M | 32.7 M | 108 M | 22.4 M | 49.5 M | 6.59 M | 14.2 M | 18.4 M | 9.88 M |
Book Value |
997 M | 1.4 B | 1.36 B | 382 M | 202 M | 143 M | 48.3 M | 118 M | 28.1 M | 25.9 M | 34.4 M | 27.2 M |
Total Shareholders Equity |
997 M | 1.4 B | 1.36 B | 382 M | 202 M | 143 M | 48.3 M | 118 M | 28.1 M | 25.9 M | 34.4 M | 27.3 M |
All numbers in USD currency
Quarterly Balance Sheet Mirati Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
42.2 M | 42.7 M | 43.2 M | 43.7 M | 44.1 M | - | 45.8 M | 45.9 M | 45.5 M | 44.5 M | 43.2 M | 41.9 M | - | 41.9 M | 41.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
183 M | 186 M | 171 M | 206 M | 174 M | - | 172 M | 192 M | 169 M | 227 M | 121 M | 115 M | 115 M | 115 M | 115 M | 49.9 M | 49.9 M | 49.9 M | 49.9 M | 26.9 M | 26.9 M | 26.9 M | 26.9 M | 14 M | 14 M | 14 M | 14 M | 15.1 M | 15.1 M | 15.1 M | 15.1 M | 9.84 M | 9.84 M | 9.84 M | 9.84 M | 5.42 M | 5.42 M | 5.42 M | 5.42 M | 38.7 M | 38.7 M | 38.7 M | 38.7 M | 5.38 M | 5.38 M | 5.38 M | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | 65 M | - | - | - | - | - | 824 K | - | - | 638 K | 371 K | 439 K | 318 K | 371 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-2.98 B | -2.81 B | -2.64 B | -2.45 B | -2.25 B | - | -1.9 B | -1.71 B | -1.51 B | -1.43 B | -1.27 B | -1.13 B | -1.13 B | -1.13 B | -1.13 B | -772 M | -772 M | -772 M | -772 M | -559 M | -559 M | -559 M | -559 M | -461 M | -461 M | -461 M | -461 M | -390 M | -390 M | -390 M | -390 M | -307 M | -307 M | -307 M | -307 M | -242 M | -242 M | -242 M | -242 M | -198 M | -198 M | -198 M | -198 M | -140 M | -140 M | -140 M | - | - | - | - | - |
Total Assets |
1.13 B | 915 M | 1.03 B | 1.2 B | 1.3 B | - | 1.42 B | 1.59 B | 1.25 B | 1.36 B | 1.38 B | 1.48 B | 1.48 B | 1.48 B | 1.48 B | 432 M | 432 M | 432 M | 432 M | 228 M | 228 M | 228 M | 228 M | 157 M | 157 M | 157 M | 157 M | 63.4 M | 63.4 M | 63.4 M | 63.4 M | 128 M | 128 M | 128 M | 128 M | 33.5 M | 33.5 M | 33.5 M | 33.5 M | 64.5 M | 64.5 M | 64.5 M | 64.5 M | 39.8 M | 39.8 M | 39.8 M | - | - | - | - | - |
Cash and Cash Equivalents |
259 M | 130 M | 242 M | 235 M | 299 M | 266 M | 305 M | 413 M | 243 M | 281 M | 330 M | 886 M | 886 M | 886 M | 886 M | 46.5 M | 46.5 M | 46.5 M | 46.5 M | 32.7 M | 32.7 M | 32.7 M | 32.7 M | 108 M | 108 M | 108 M | 108 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 49.5 M | 49.5 M | 49.5 M | 49.5 M | 6.59 M | 6.59 M | 6.59 M | 6.59 M | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 18.4 M | 18.4 M | 18.4 M | - | 9.88 M | - | - | - |
Book Value |
946 M | 729 M | 863 M | 997 M | 1.13 B | - | 1.25 B | 1.4 B | 1.08 B | 1.13 B | 1.26 B | 1.36 B | 1.36 B | 1.36 B | 1.36 B | 382 M | 382 M | 382 M | 382 M | 202 M | 202 M | 202 M | 202 M | 143 M | 143 M | 143 M | 143 M | 48.3 M | 48.3 M | 48.3 M | 48.3 M | 118 M | 118 M | 118 M | 118 M | 28.1 M | 28.1 M | 28.1 M | 28.1 M | 25.9 M | 25.9 M | 25.9 M | 25.9 M | 34.4 M | 34.4 M | 34.4 M | - | - | - | - | - |
Total Shareholders Equity |
946 M | 729 M | 863 M | 997 M | 1.13 B | 1.11 B | 1.25 B | 1.4 B | 1.08 B | 1.13 B | 1.26 B | 1.36 B | 1.36 B | 1.36 B | 1.36 B | 382 M | 382 M | 382 M | 382 M | 202 M | 202 M | 202 M | 202 M | 143 M | 143 M | 143 M | 143 M | 48.3 M | 48.3 M | 48.3 M | 48.3 M | 118 M | 118 M | 118 M | 118 M | 28.1 M | 28.1 M | 28.1 M | 28.1 M | 25.9 M | 25.9 M | 25.9 M | 25.9 M | 34.4 M | 34.4 M | 34.4 M | - | 27.3 M | - | - | - |
All numbers in USD currency